Abstract:Decreased nicotinamide adenine dinucleotide (NAD + ) levels contribute to various pathologies such as ageing, diabetes, heart failure and ischemia–reperfusion injury (IRI). Nicotinamide riboside (NR) has emerged as a promising therapeutic NAD + precursor due to efficient NAD + elevation and was recently shown to be the only agent able to reduce cardiac IRI in models employing clinically relevant anesthesia. However, through which metabolic pathway(s) NR mediates IRI protection remains unknown. Furthermore, the influence of insulin, a known modulator of cardioprotective efficacy, on the protective effects of NR has not been investigated. Here, we used the isolated mouse heart allowing cardiac metabolic control to investigate: (1) whether NR can protect the isolated heart against IRI, (2) the metabolic pathways underlying NR-mediated protection, and (3) whether insulin abrogates NR protection. NR protection against cardiac IRI and effects on metabolic pathways employing metabolomics for determination of changes in metabolic intermediates, and 13 C-glucose fluxomics for determination of metabolic pathway activities (glycolysis, pentose phosphate pathway (PPP) and mitochondrial/tricarboxylic acid cycle (TCA cycle) activities), were examined in isolated C57BL/6N mouse hearts perfused with either (a) glucose + fatty acids (FA) ("mild glycolysis group"), (b) lactate + pyruvate + FA ("no glycolysis group"), or (c) glucose + FA + insulin ("high glycolysis group"). NR increased cardiac NAD + in all three metabolic groups. In glucose + FA perfused hearts, NR reduced IR injury, increased glycolytic intermediate phosphoenolpyruvate (PEP), TCA intermediate succinate and PPP intermediates ribose-5P (R5P) / sedoheptulose-7P (S7P), and was associated with activated glycolysis, without changes in TCA cycle or PPP activities. In the "no glycolysis" hearts, NR protection was lost, whereas NR still increased S7P. In the insulin hearts, glycolysis was largely accelerated, and NR protection abrogated. NR still increased PPP intermediates, with now high 13 C-labeling of S7P, but NR was unable to increase metabolic pathway activities, including glycolysis. Protection by NR against IRI is only present in hearts with low glycolysis, and is associated with activation of glycolysis. When activation of glycolysis was prevented, through either examining "no glycolysis" hearts or "high glycolysis" hearts, NR protection was abolished. The data suggest that NR's acute cardioprotective effects are mediated through glycolysis activation and are lost in the presence of insulin because of already elevated glycolysis.

Nicotinamide Riboside-Driven Modulation of SIRT3/mtROS/JNK Signaling Pathways Alleviates Myocardial Ischemia-Reperfusion Injury

Nicotinamide riboside attenuates myocardial ischemia-reperfusion injury via regulating SIRT3/SOD2 signaling pathway

Nicotinamide ribose ameliorates myocardial ischemia/reperfusion injury by regulating autophagy and regulating oxidative stress

Nicotinamide Riboside Alleviates Cardiac Dysfunction and Remodeling in Pressure Overload Cardiac Hypertrophy

GW27-e0632 NR Reduced Myocardial Ischemia-Reperfusion Injury by Improving Mitochondrial Biogenesis and Reducing Excessive Autophagy Via Sirt3-PGC-1α/P53 Pathway

Nicotinamide riboside alleviates hypoxia/reoxygenation injury in adult mouse cardiomyocytes via Sirt3-PGC-1α pathway

Insulin and glycolysis dependency of cardioprotection by nicotinamide riboside

Nicotinamide Riboside Attenuates Injury of Mouse Diabetic Cardiomyopathy and Possible Mechanism

Nicotinamide Mononucleotide Attenuates Isoproterenol-Induced Cardiac Fibrosis by Regulating Oxidative Stress and Smad3 Acetylation.

Exogenous Supplemental NAD+ Protect Myocardium Against Myocardial Ischemic/reperfusion Injury in Swine Model.

NAD + administration decreases microvascular damage following cardiac ischemia/reperfusion by restoring autophagic flux

Nicotinamide riboside: A promising therapy for MI-induced acute kidney injury by upregulating nicotinamide phosphoribosyltransferase-mediated NAD levels

Exogenous NADPH Ameliorates Myocardial Ischemia–reperfusion Injury in Rats Through Activating AMPK/mTOR Pathway

Exogenous Nad(+) Supplementation Protects H9c2 Cardiac Myoblasts Against Hypoxia/Reoxygenation Injury Via Sirt1-P53 Pathway

Administration of nicotinamide riboside prevents oxidative stress and organ injury in sepsis

Acute Treatment with Nicotinamide Riboside Chloride Reduces Hippocampal Damage and Preserves the Cognitive Function of Mice with Ischemic Injury

Protection Effect of Nicotinamide on Cardiomyoblast Hypoxia/re-Oxygenation Injury: Study of Cellular Mitochondrial Metabolism.

ROCK-dependent ATP5D Modulation Contributes to the Protection of Notoginsenoside NR1 Against Ischemia-Reperfusion-induced Myocardial Injury.

Resveratrol Inhibits Ischemia-Induced Myocardial Senescence Signals and NLRP3 Inflammasome Activation.

Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level

Salvianolic Acid B Alleviated Myocardial Ischemia-Reperfusion Injury Via Modulating SIRT3-mediated Crosstalk Between Mitochondrial ROS and NLRP3